FDA Approves Capmatinib for Metastatic NSCLC
FDA Approves New Acalabrutinib Formulation
AstraZeneca Plans to Withdraw an Olaparib Indication for Ovarian Cancer
FDA Approves Label Expansion for VENTANA MMR RxDx Panel
FDA Approves Darolutamide + Docetaxel for mHSPC
FDA Approves Fam-Trastuzumab-Deruxtecan-nxki for HER2-Low Breast Cancer
FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumor
CMS Announces CY 2023 HOPPS Proposed Rule
CMS Stakeholder Call: Strategic Plan Update
CMS Announces CY 2023 PFS Proposed Rule
CMS Announces the Enhancing Oncology Model
FDA Approves Dabrafenib + Trametinib for Metastatic Solid Tumors
FDA Approves Lisocabtagene Maraleucel for Refractory Large B-Cell Lymphoma
FDA Approves FoundationOne CDx for Entrectinib
FDA Approves Pegfilgrastim-pbbk Biosimilar
FDA Approves Two Nivolumab-Based Regimens for Esophageal Squamous Cell Carcinoma
FDA Approves Tisagenlecleucel for R/R Follicular Lymphoma
FDA Approves Ivosidenib in Combination for Acute Myeloid Leukemia
Eisai Provides Lenvatinib Dose Reductions at No Cost
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Breast Cancer
ASCO's Guideline Update Includes Oncotype DX in Early-Stage Breast Cancer
FDA Approves Bevacizumab-maly Biosimilar for Colorectal Cancer
Secretary of HHS Extends COVID-19 Public Health Emergency
FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Prostate Cancer
FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma
FDA approves nivolumab and relatlimab-rmbw for melanoma
FDA Approves FoundationOne®CDx in Non-Small Cell Lung Cancer
FDA Approves BRACAnalysis® CDx in Early-Stage Breast Cancer
FDA Approves Olaparib for High-Risk Early Breast Cancer
